Medtronic plc (NYSE:MDT) Q3 2023 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Ryan Weispfenning - Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Bob White - Executive Vice President and President, Medical Surgical Portfolio Brett Wall - Executive Vice President and President, Neuroscience Portfolio Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President ...

41st annual J.P. Morgan healthcare conference Geoff Martha, Chairman and CEO January 9, 2023 San Francisco Forward-looking statements, non-GAAP financial measures, and comparisons Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

Medtronic plc (NYSE:MDT) 5th Annual Evercore ISI HealthCONx Conference Call Summary Company Overview - **Company**: Medtronic plc - **Date**: November 29, 2022 - **Participants**: Geoff Martha (CEO), Karen Parkhill (CFO), Vijay Kumar (Evercore ISI) Key Points Financial Performance - Medtronic reported a fiscal Q2 topline miss but achieved EPS at the high end of the range, indicating effective cost management despite revenue challenges [4][5] - The company revised its guidance downward for the second half of FY2023 due to slower recovery in procedures and supply chain issues [4][12] Business Transformation and Growth Drivers - Medtronic is undergoing significant changes to its operating model and culture to enhance competitiveness and drive growth [5][9] - Key growth areas identified include: - **Cardiac Rhythm Management**: Consistently outperforming [8] - **Structural Heart**: Strong performance noted [8] - **Neurovascular, ENT, and Cardiac Surgery**: All showing positive results [8] - **Diabetes and Surgical Robotics**: Positioned for strong growth in the coming years [9][10] Supply Chain and Market Recovery - Supply chain challenges were more prolonged than anticipated, particularly affecting the Surgical Innovations business [12][13] - The company expects normalization of supply chain issues throughout FY2023 [16] - Recovery in elective procedures is uneven across markets, with notable strength in orthopedics and spine [18][19] China VBP Impact - Approximately 15% to 20% of the guidance reduction is attributed to changes in provincial tenders in China, which were expected to occur later [22][24] - The neurovascular business in China is significant, with expectations for future growth despite recent declines [26] Product Pipeline and Innovations - New product launches, including the Evolut FX valve and advancements in robotic surgery, are anticipated to drive growth in the second half of FY2023 [28][29] - The Hugo robotic system is gaining traction, with positive feedback from surgeons and competitive performance noted at recent conferences [34][35] Diabetes Segment - The 780G system is expected to replicate international success in the U.S. market, driven by strong patient feedback and clinical results [53][54] - Medtronic is investing in a robust pipeline for diabetes management, including the Simplera sensor, which is a zero-calibration device [55][57] Financial Outlook and Capital Allocation - FX headwinds are projected to impact FY2024 EPS by approximately $0.36, equating to about 7% growth off current guidance [59] - Medtronic is balancing shareholder returns through dividends and share repurchases while investing in long-term growth drivers [70][72] Strategic Focus - Recent divestitures in non-core areas are part of a strategy to streamline operations and focus on high-growth segments [73][74] - The company aims for a higher level of growth through strategic portfolio management and capital allocation [74] Additional Insights - Medtronic is committed to maintaining a strong balance sheet and dividend during challenging market conditions [5] - The company is focused on enhancing its competitive position through innovation and operational improvements [9][10]

Medtronic plc (NYSE:MDT) Q2 2023 Earnings Conference Call November 22, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Brad Welnick - Investor Relations Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Brett Wall - Executive Vice President and President, Neu ...

Medtronic plc (NYSE:MDT) Conference Call Summary Industry Overview - The conference was part of the Morgan Stanley 20th Annual Global Healthcare Conference held on September 12, 2022, focusing on the medical technology sector, specifically Medtronic plc. Key Points and Arguments Market Dynamics - Staffing issues in the healthcare sector are improving, nearing pre-pandemic levels for most procedures, although some areas still lag behind [3][4] - Supply chain challenges, particularly with plastics, resins, and semiconductors, are showing signs of improvement, although semiconductor issues may persist longer [3][4] Capital and Revenue - Capital expenditure remains a small portion of revenue, tied to profitable procedures, with a healthy capital environment observed [6] - Medtronic is focusing on capital allocation to higher growth areas across its 20 operating units [8] Business Optimization - The company is decentralizing operations to enhance innovation and performance accountability, which has exceeded expectations [10] - Medtronic is leveraging its scale by focusing on strategic customers, technology platforms, and centralizing its supply chain [12] Direct-to-Consumer (DTC) Strategy - Medtronic is shifting towards a consumer-focused approach, particularly in diabetes and renal denervation (RDN) markets, to drive patient awareness and engagement [17][18] M&A and Portfolio Management - The company is actively managing its portfolio through acquisitions and divestitures, focusing on higher growth segments and optimizing capital allocation [20][21] - Recent acquisitions, such as Affera, are aimed at enhancing Medtronic's cardiac ablation solutions [22][23] Research and Development Focus - Key areas of investment include robotics (HUGO), atrial fibrillation (AFIB), structural heart, and diabetes, with a focus on innovative solutions and market leadership [25][26] Pricing Power and Inflation - Medtronic is experiencing a shift towards positive pricing power, with efforts to manage costs and improve margins despite inflationary pressures [34][36] Product Development and Ecosystem - The company is enhancing its surgical robotics ecosystem, focusing on integrating digital surgery platforms and improving the overall offering [42][45] Sales Strategy and Market Rollout - Medtronic plans to leverage its existing interventional cardiology sales force for the rollout of new products, ensuring efficient training and integration into current operations [50][51] Additional Important Insights - The company is focusing on building a more performance-based culture through revised incentives tied to growth and market share [10] - Medtronic is exploring creative structures for venture investments to mitigate risks associated with new acquisitions [22] - The company is committed to reducing the number of suppliers to enhance cost efficiency in its supply chain [36] This summary encapsulates the key discussions and strategic directions outlined during the conference call, highlighting Medtronic's focus on innovation, market dynamics, and operational efficiency in the medical technology sector.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. ...

Medtronic plc (NYSE:MDT) Q1 2023 Earnings Conference Call August 23, 2022 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Karen Parkhill - CFO Sean Salmon - EVP and President, Cardiovascular Portfolio Bob White - EVP and President, Medical Surgical Portfolio Brett Wall - EVP and President, Neuroscience Portfolio Que Dallara - EVP and President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Travis S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File No. 1-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State or other ...